Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the present study is to use positron emission tomography brain imaging to investigate D3 occupancy of buspirone, an FDA-approved anxiolytic which acts as a serotonin partial agonist but has recently been identified as a D3 antagonist. It is hypothesized that clinically relevant doses of buspirone will occupy the D3 receptor.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Centre for Addiction and Mental Health
• Treatments: Buspirone; Dopamine; Dopamine Agents

Criteria

Inclusion Criteria:

• 19 years or older

Exclusion Criteria:

• Medical condition including cardiovascular, renal, hepatic or cerebrovascular diseases

• History of or current neurological illnesses including seizure disorders, migraine, multiple sclerosis, movement disorders, head trauma, CVA or CNS tumor, - Present or past psychiatric condition including mood, anxiety, psychotic disorders and substance abuse and/or dependence.

• Condition that precludes use of buspirone or that will interfere with participation in the present study (such as hypersensitive to buspirone hydrochloride).

• Pregnancy or breastfeeding.

• Presence of metal objects in the body or implanted electronic devices, that preclude safe MR scanning.

• Claustrophobia.

• Current use or use during the previous month of medication that may affect the CNS, including monoamine oxidase inhibitor (MAOI) or positive during drug screening for drugs of abuse or any medication that could increase the risk of buspirone administration.

• Exposure to radiation in the last 12 month exceeding permissible limit for subjects participating in research.